Study of XL999 in Patients With Previously Treated Ovarian Cancer

Exclusion Criteria

• •Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
• •Use of an investigational drug or cytotoxic chemotherapy within 30 days of XL999 treatment
• •Prior anticancer therapy targeting VEGF (eg, bevacizumab, sorafenib, or sunitinib)
• •More than two prior systemic non-platinum cytotoxic chemotherapy regimens
• •Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to other medications administered \>30 days prior to study enrollment
• •History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
• •Uncontrolled and/or intercurrent illness
• •Patients who are pregnant or breastfeeding
• •Known human immunodeficiency virus (HIV)